Clinical Trial Update: Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial examining consolidation with Y-90 ibritumomab tiuxetan after R-CHOP induction in patients with high-risk Follicular Lymphoma (per FLIPI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas | Conditions: Follicular Lymphoma | Phase 2 | Status: UNKNOWN